Compare Z & KYMR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | Z | KYMR |
|---|---|---|
| Founded | 2004 | 2015 |
| Country | United States | United States |
| Employees | 7058 | N/A |
| Industry | Business Services | Medicinal Chemicals and Botanical Products |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.0B | 6.4B |
| IPO Year | N/A | 2020 |
| Metric | Z | KYMR |
|---|---|---|
| Price | $30.95 | $107.42 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 25 | 26 |
| Target Price | $79.45 | ★ $107.72 |
| AVG Volume (30 Days) | ★ 4.7M | 970.4K |
| Earning Date | 05-06-2026 | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $39,211,000.00 |
| Revenue This Year | $17.77 | $10.61 |
| Revenue Next Year | $13.31 | $8.17 |
| P/E Ratio | $499.78 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $29.23 | $36.88 |
| 52 Week High | $93.88 | $130.05 |
| Indicator | Z | KYMR |
|---|---|---|
| Relative Strength Index (RSI) | 35.33 | 69.41 |
| Support Level | N/A | $68.35 |
| Resistance Level | $47.41 | N/A |
| Average True Range (ATR) | 1.68 | 6.85 |
| MACD | -0.05 | 3.23 |
| Stochastic Oscillator | 25.25 | 60.04 |
Zillow Group Inc is a real estate technology company offering a digital platform that connects real estate customers with sellers, agents, loan officers, and other real estate-related professionals. With its tools and resources, Zillow helps real estate professionals grow their businesses, and for renters and housing providers, it offers a marketplace along with a set of end-to-end products and services to streamline applications, leases, payments, and more. The group operates various brands such as Zillow, Zillow Home Loans, Zillow Rentals, Zillow New Construction, Trulia, StreetEasy, Out East, HotPads, Follow Up Boss, ShowingTime, dotloop, and Zillow Closing. Its ecosystem spans the entire home journey from shopping to renting, buying, selling, and financing real estate.
Kymera Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to reinventing the treatment of human disease through the development of differentiated medicines that address health problems and meaningfully improve patients' lives. It is committed to novel technologies to address targets that have known disease-causing biology, but which have not been drugged, or have been inadequately drugged, often based on limitations of existing technologies. Its approach is intended to discover and develop a new generation of medicines in a disease-agnostic manner. Its product pipelines are STAT6, and IRAK4.